Last Updated : June 10, 2024
Details
FilesGeneric Name:
treosulfan
Project Status:
Complete
Therapeutic Area:
Conditioning treatment prior to stem cell transplantation for acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS)
Manufacturer:
Medexus Pharmaceuticals Inc.
Call for patient/clinician input open:
Brand Name:
Trecondyv
Project Line:
Reimbursement Review
Project Number:
PC0324-000
Call for patient/clinician input closed:
Tumour Type:
Leukemia
NOC Status at Filing:
Post NOC
Performance Metric:
Achieved
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
In combination with fludarabine as part of conditioning treatment prior to allogeneic hematopoietic stem cell transplantation (alloHSCT) in adult patients with AML or MDS at increased risk for standard conditioning therapies.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
In combination with fludarabine as part of conditioning treatment prior to allogeneic hematopoietic stem cell transplantation (alloHSCT) in adult patients with AML or MDS at increased risk for standard conditioning therapies.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | June 02, 2023 |
|---|---|
| Call for patient/clinician input closed | July 28, 2023 |
| Clarification: - Patient input submission received from The Leukemia & Lymphoma Society of Canada (LLSC) | |
| Submission received | July 14, 2023 |
| Submission accepted | August 08, 2023 |
| Clarification: - Submission was not accepted for review on 28 Jul 23 | |
| Review initiated | August 09, 2023 |
| Draft CADTH review report(s) provided to sponsor for comment | November 09, 2023 |
| Deadline for sponsors comments | November 21, 2023 |
| CADTH review report(s) and responses to comments provided to sponsor | December 21, 2023 |
| Expert committee meeting (initial) | January 10, 2024 |
| Draft recommendation issued to sponsor | January 22, 2024 |
| Draft recommendation posted for stakeholder feedback | February 01, 2024 |
| End of feedback period | February 15, 2024 |
| Final recommendation issued to sponsor and drug plans | February 28, 2024 |
| Final recommendation posted | March 18, 2024 |
| Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | March 13, 2024 |
| CADTH review report(s) posted | June 06, 2024 |
Files
Last Updated : June 10, 2024